TY - JOUR
T1 - Decreased CX3CL1 levels in the cerebrospinal fluid of patients with Alzheimer's disease
AU - Perea, Juan R.
AU - Lleó, Alberto
AU - Alcolea, Daniel
AU - Fortea, Juan
AU - Ávila, Jesús
AU - Bolós, Marta
PY - 2018/9/7
Y1 - 2018/9/7
N2 - © 2018 Perea, Lleó, Alcolea, Fortea, ávila and Bolós. Alzheimer's disease (AD) is a neurodegenerative disease characterized by the presence of neurofibrillary tangles, constituted by tau protein, and plaques formed by amyloid-beta protein. The disease courses with high neural damage, which leads to memory loss and death. Here we analyzed the presence of CX3CL1, a chemokine expressed by neurons, in cerebrospinal fluid (CSF) samples from control subjects and patients with mild cognitive impairment and AD dementia. CX3CL1 was decreased in the CSF of AD dementia patients compared to control subjects. However, there was not difference in plasma samples from the same subjects.
AB - © 2018 Perea, Lleó, Alcolea, Fortea, ávila and Bolós. Alzheimer's disease (AD) is a neurodegenerative disease characterized by the presence of neurofibrillary tangles, constituted by tau protein, and plaques formed by amyloid-beta protein. The disease courses with high neural damage, which leads to memory loss and death. Here we analyzed the presence of CX3CL1, a chemokine expressed by neurons, in cerebrospinal fluid (CSF) samples from control subjects and patients with mild cognitive impairment and AD dementia. CX3CL1 was decreased in the CSF of AD dementia patients compared to control subjects. However, there was not difference in plasma samples from the same subjects.
KW - Alzheimer's disease
KW - CX3CL1
KW - Human CSF
KW - Inflammation
KW - Microglia
KW - Tau
U2 - 10.3389/fnins.2018.00609
DO - 10.3389/fnins.2018.00609
M3 - Article
C2 - 30245615
SN - 1662-4548
VL - 12
JO - Frontiers in Neuroscience
JF - Frontiers in Neuroscience
M1 - 609
ER -
